Anika Therapeutics | ANIK - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Abbott USD 52.06B 69M 2026-03
Agenus USD -199.08M 22.15M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 465.53M 148.45M 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Heron Therapeutics USD 6.91M 2.23M 2026-06
Insmed USD 757.49M 52.64M 2026-06
Integra LifeSciences USD 1.04B 971K 2026-06
Intrexon USD 43.17M 75.33M 2024-06
J&J USD 84.97B 3.78B 2026-06
Karyopharm Therapeutics USD -265.65M 27.28M 2026-03
Ligand Pharmaceuticals USD 967.52M 29.81M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merit Medical Systems USD 1.68B 53.08M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 69.57B 3.24B 2026-06
Smith & Nephew USD 5.18B 356M 2026-06
Stryker USD 22.98B 559M 2026-03
Veracyte USD 1.39B 44M 2026-06
Xencor USD 503.23M 12.4M 2026-06
Zimmer Biomet Holdings USD 12.63B 49.1M 2026-06